HomeAI · summaries
Storia in 20 fonti
Merck, Moderna say melanoma vaccine meets goals in large trial | CBC News
Merck and Moderna report that a personalized mRNA vaccine helped prevent skin cancer from returning in high-risk patients. Observers greeted the news with enthusiasm but noted that full data from the ongoing late-stage study has yet to be released.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma
At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and stopped its spread, sparking a surge in Moderna…
- ·
healio.com
mRNA melanoma vaccine-pembrolizumab combo shows survival gains in late-stage trial
A phase 3 trial found that a combination of intismeran autogene plus pembrolizumab improved recurrence-free and distant metastasis-free survival in patients with high-risk…
